Patient P-01588
Synthetic patientNBL-101 · Day 118 · 25–34 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
50%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient accepted — Started GI-04 in the companion
- Day 65 ME-01 recommended — Monitoring Escalation ME-01
- Day 66 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 66 Patient accepted — Started ME-01 in the companion
- Day 69 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 72 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability-7
- Inflammatory activity-5
- Treatment adherence+5
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −26%
- GI Support Protocol GI-04Day 57Result: symptom burden −32%
- Monitoring Escalation ME-01Day 65Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
73%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 94% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion30.9/100
improving · -4.2 vs previous 14 d
Toxicity
Blood47.2/100
worsening · +4.8 vs previous 14 d
Sleep quality
Wearable51.5/100
improving · +3.1 vs previous 14 d
Energy level
Daily log4.6/10
improving · +0.4 vs previous 14 d
Stress level
Daily log5.4/10
stable · +0.0 vs previous 14 d
Steps
Wearable8,440
stable · -2 vs previous 14 d
Adherence
Companion63 %
stable · +0.3 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 57 from the failing basin, 31 from restoration.
Good elements to keep
- GI Support Protocol GI-04intervention · steering +53.9
- Dietary Support Protocol NP-02intervention · steering +39.4
- Monitoring Escalation ME-01intervention · steering +4.9
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- FUT2 non-secretorhidden · steering -10.6
- Rapid metabolizerhidden · steering -8
- Low microbial diversityhidden · steering -7.7
- Spicy / capsaicindetractor · GI +3.8 next day
- Dietary fat loaddetractor · GI +3.7 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin+3.8detractor · 95%
- Dietary fat load+3.7detractor · 95%
- Insoluble fibre+2.3detractor · 80%
- Histamine load+2.1detractor · 73%
- Simple carbohydrates+2.1detractor · 69%
- Alcohol+1no signal · 33%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↓45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Drug metabolism and exposure ↑20
- BloodToxicity index 47
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 2.2 · butyrate capacity 23/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 7.5 h
- Steps
- 8,168
- Resting HR
- 68 bpm
Daily log: GI score 31, nutritional resilience 54, adherence 63.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.